Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions While combination therapy with clopidogrel and ASA remains the basis of antiplatelet therapy in acute coronary syndrome (ACS) patients, each combined therapy of P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) and ASA can be considered for some groups depending on the clinical presentation and subsequent management for patients with ACS. Indexing Status Subject indexing assigned by CRD MeSH Acute Coronary Syndromes; Adenosine; Cost-Benefit Analysis; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca AccessionNumber 32012000686 Date abstract record published 28/09/2012 |